Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HR+/HER2- metastatic disease

- PMLiVE

Novartis’ Kisqali shows long-term improvements in breast cancer patients

Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’

- PMLiVE

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

FDA approved the antibody-drug conjugate in this indication in April 2020

- PMLiVE

UK approval for Seagen’s oral HER2 inhibitor Tukysa

MHRA has authorised drug for HER2-positive advanced breast cancer

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

- PMLiVE

Gilead agrees $21bn buyout of Immunomedics

Pharma company gains rights to ADC Trodelvy

- PMLiVE

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu

- PMLiVE

Google’s DeepMind AI outperforms doctors on breast cancer screening

System reduced false positive and false negative decisions

Roche Basel Switzerland

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Could face tough competition soon from a number of rivals

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links